Updates are available Correction dated 2023-03-17
Click to view Correction: https://doi.org/10.1038/s41590-023-01491-4
-
Authors
Steele, Maria M.
Jaiswal, Abhinav
Delclaux, Ines
Dryg, Ian D.
Murugan, Dhaarini
Femel, Julia https://orcid.org/0000-0002-0254-316X
Son, Sunny
du Bois, Haley
Hill, Cameron
Leachman, Sancy A.
Chang, Young H. https://orcid.org/0000-0001-8764-1959
Coussens, Lisa M. https://orcid.org/0000-0003-2389-1865
Anandasabapathy, Niroshana
Lund, Amanda W. https://orcid.org/0000-0001-7389-9983
-
Funding
Funding for this research was provided by:
U.S. Department of Health &Human Services | National Institutes of Health (P30-CA069533)
U.S. Department of Health &Human Services | National Institutes of Health (P30CA016087)
U.S. Department of Health &Human Services | National Institutes of Health (R01CA238163)
U.S. Department of Health &Human Services | National Institutes of Health (T32CA106195)
U.S. Department of Health &Human Services | National Institutes of Health (T32GM136542)
U.S. Department of Health &Human Services | National Institutes of Health (F31CA268726-01A1)
U.S. Department of Health &Human Services | National Institutes of Health (P30-CA069533)
U.S. Department of Health &Human Services | National Institutes of Health (R56 AR078686)
U.S. Department of Health &Human Services | National Institutes of Health (R01 AR080436)
Cancer Research Institute
Melanoma Research Alliance (403191)
American Cancer Society (RSG-18-169-01-LIB)
Vetenskapsrådet (2016-00215)
American Association for Cancer Research (SU2C-AACR-DT14-14)
Brenden-Colson Center for Pancreatic Health
- License Information
-
More Information
Article History
Received: 11 May 2022
Accepted: 25 January 2023
First Online: 27 February 2023
Change Date: 17 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-023-01491-4
Competing interests
: A.W.L. declares having provided consulting services for AGS Therapeutics. L.M.C. declares having provided consulting services for Cell Signaling Technologies, AbbVie, the Susan G Komen Foundation and Shasqi, has received reagents and/or research support from Cell Signaling Technologies, Syndax Pharmaceuticals, ZelBio, Inc., Hibercell, Inc. and Acerta Pharma and has participated in advisory boards for Pharmacyclics, Syndax, Carisma, Verseau, CytomX, Kineta, Hibercell, Cell Signaling Technologies, Alkermes, Zymeworks, Genenta Sciences, Pio Therapeutics Pty, Ltd., PDX Pharmaceuticals, the AstraZeneca Partner of Choice Network, the Lustgarten Foundation and the NIH/NCI-Frederick National Laboratory Advisory Committee. N.A. declares having provided consulting/lecture services for Cellino Biotech, Immunitas, Shennon Biotechnologies and Janssen. The other authors declare no competing interests.
